NPC1 as a Modulator of Disease Severity and Viral Entry of SARS-CoV-2

dc.creatorVial, Cecilia
dc.creatorCalderón, Juan Francisco
dc.creatorKlein, Andrés
dc.date.accessioned2021-08-17T16:56:37Z
dc.date.accessioned2023-05-19T14:53:18Z
dc.date.available2021-08-17T16:56:37Z
dc.date.available2023-05-19T14:53:18Z
dc.date.created2021-08-17T16:56:37Z
dc.date.issued2020
dc.identifierCurrent Molecular Medicine, 2020, 20: 1-3
dc.identifierhttps://dx.doi.org/10.2174/1566524020666200713175426
dc.identifierhttp://hdl.handle.net/11447/4342
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/6303503
dc.description.abstractThe COVID-19 plague is hitting mankind. Several viruses, including SARS-CoV-1, MERS-CoV, EBOV, and SARS-CoV-2, use the endocytic machinery to enter the cell. Genomic variants in NPC1, which encodes for the endo-lysosomal Niemann-Pick type C1 protein, restricts the host-range of viruses in bats and susceptibility to infections in humans. Lack of NPC1 and its pharmacological suppression inhibits many viral infections including SARS-CoV-1 and Type I Feline Coronavirus Infection. Antiviral effects of NPC1-inhibiting drugs for COVID-19 treatment should be explored.
dc.languageen
dc.subjectCOVID-19
dc.subjectSARS-Cov-2
dc.subjectNiemann-Pick C1
dc.subjectModifier gene
dc.subjectDrug repurposing
dc.subjectVirus
dc.subjectInfection
dc.titleNPC1 as a Modulator of Disease Severity and Viral Entry of SARS-CoV-2
dc.typeArticle


Este ítem pertenece a la siguiente institución